Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results